Across TCGA pan-cancer cohorts, TSC22D2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TSC22D2 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher TSC22D2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TSC22D2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, UCEC, and ACC are the cancer types where TSC22D2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.232	0.787	.002	17	view →
UCEC	DFS	Median	All	0.933	0.626	.025	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
ESCA	OS	Median	II,III,IV	0.327	0.690	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TSC22D2 tumor-vs-normal RNA expression · all TSC22D2 data types